A phase 2 study of dasatinib-combined chemotherapy in patients with relapsed Philadelphia chromosome-positive acute lymphoid leukemia.
Phase 2
- Conditions
- Philadelphia chromosome positive acute lymphoblastic leukemia
- Registration Number
- JPRN-UMIN000005352
- Lead Sponsor
- Japan Adult Leukemia Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 19
Inclusion Criteria
Not provided
Exclusion Criteria
1.Severe comorbidity (infection, lung disease, hypertension, heart failure, diabetes mellitus) 2.Recent history of ischemic heart disease 3.Other active neoplasms 4.Pregnant and/or lactating woman 5.Psychological disorders 6.Positive HBs antigen and/or anti-HIV antibody 7.Received allogeneic stem cell transplantation within 100 days 8. Receiving immunosuppressive agents (cyclosporine, tacrolimus)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Complete hematological remission rate in induction therapy
- Secondary Outcome Measures
Name Time Method Hematological remission rate Complete cytogenetical remission rate Major molecular remission rate Overall survival rate at 1 year Treatment related toxicity